https://orcid.org/0000-0002-4396-5246
References
- Schmidt AM. Diabetes mellitus and cardiovascular disease: emerging therapeutic approaches. Arterioscler Thromb Vasc Biol. 2019;39(4):558–568.
- Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436–2443.
- Pulipati VP, Ravi V, Pulipati P. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Eur J Prev Cardiol. 2020;27(18):1922–1930.
- Marso SP, Holst AG, Vilsbøll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376(9):891–892.
- Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
- Accessed on 2020 Jun 12th. https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-National-Average-Drug-Acquisition-Cost-/a4y5-998d
- Levy J, Rosenberg M, Vanness D. A transparent and consistent approach to assess US outpatient drug costs for use in cost-effectiveness analyses. Value Health. 2018;21(6):677–684.
- Suissa S. Calculation of number needed to treat. N Engl J Med. 2009;361(4):424–425.
- Husain M, Bain SC, Holst AG, et al. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol. 2020;19(1):1–11.
- Verma S, Bain SC, Buse JB, et al. Occurence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular events: a post hoc analysis of a randomized clinical trial. JAMA Cardiol. 2019;4(12):1214–1220.
- Hernandez AF, Green JB, Janmohamed S, et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
- Wilding JP, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
- Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143(21):e984–e1010.
- Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367.
- Guzauskas GF, Rind DM, Fazioli K, et al. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. J Manag Care Spec Pharm. 2021;27(4):455–468.
- Rind D, Guzauskas G, Fazioli K, et al. Oral semaglutide for type 2 diabetes: effectiveness and value. Boston, MA, USA: Institute for Clinical and Economic Review; 2019.
- Risebrough NA, Baker TM, Zhang L, et al. Lifetime cost-effectiveness of oral semaglutide versus dulaglutide and liraglutide in patients with type 2 diabetes inadequately controlled with oral antidiabetics. Clin Ther. 2021;43(11):1812–1826.
- Bain SC, Hansen BB, Malkin SJ, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Therapy. 2020;11(1):259–277.
- A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). NORDISK, NOVO. s.l.: accessed from Clinincaltrials.gov on 2021 Jun 8th.
- Husereau D, Drummond M, Petrou S, et al., ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
- Brunton SA, Mosenzon O, Wright Jr EE Jr. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how? Postgrad Med. 2020;132(sup2):48–60.
- Morales J, Shubrook JH, Skolnik N. Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgrad Med. 2020;132(8):687–696.
- Cavaiola TS, Kiriakov Y, Reid T. Primary care management of patients with type 2 diabetes: overcoming inertia and advancing therapy with the use of injectables. Clin Ther. 2019;41(2):352–367.